Navigation Links
Reportlinker Adds World Botulinum Toxin Market Report
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

World Botulinum Toxin Market

http://www.reportlinker.com/p0119494/World-Botulinum-Toxin-Market.html

This report analyzes the worldwide markets for Botulinum Toxin in Millions of US$. The Study Analyzes the Market for 'Botulinum Toxin' by the Following Segments: Cosmetic, and Therapeutic (Movement Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder, & Spasticity) The report provides separate comprehensive analytics for the USA, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 19 companies including many key and niche players worldwide such as Allergan, Inc., Ipsen Group, Lanzhou Institute of Biological Products, Metabiologics, Inc., Metabiologics Inc., Merz Pharmaceuticals GmbH, Mentor Corporation, Medy-Tox Incorporated, Medicis Pharmaceutical Corporation, and Solstice Neurosciences, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

BOTULINUM TOXIN

A GLOBAL STRATEGIC BUSINESS REPORT MCP-1833

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1

Disclaimers I-2

Data Interpretation & Reporting Level I-2

Product Definitions and Scope of Study I-3

Cosmetic Applications I-3

Therapeutic Applications I-3

II. EXECUTIVE SUMMARY

1. Industry Overview II-1

A Prelude II-1

Botulinum Toxin: "The Science, The Hopes & the Risks" II-1

Future Opportunities Span Beyond The Developed Markets II-2

A Peek Into Noteworthy Trends & Issues II-2

Changing Consumer Sentiments II-2

Aging Population: A Weighty Demographic Driver II-3

Unmet Medical Needs Encourage Off-Label Use: A Cause for

Concern or Jubilation? II-3

Need for Physician Education Rises With Growing Off Label Usage II-3

High Voltage Ad Campaigns Boost Patient Awareness II-4

Societal Pressure to Look Young Drives up Demand for Facial

Aesthetics II-4

Cosmetic Botulinum Toxin to Feel the Pinch of the Recession II-4

Financing of Non-Reimbursed Healthcare: The Need of the Hour II-5

Combination Therapies: A Double Whammy Success II-5

Short Lived Aesthetic Effects: A Strong Business Case for

Revision Treatments II-6

Consolidation Blows in the Aesthetic Healthcare Industry II-6

Undesirable Side Effects: A Challenge to Reckon With II-6

Immunogenicity Undermines Patient Compliance II-7

Stringent Regulations Delay Market Approval & Put

Reimbursements in Limbo II-7

Non-Injectable Alternatives to Turn On the Heat II-7

Fears of Terrorism & Biological Warfare Thwart International

Trade II-8

Competition II-8

Allergan Wields the Scepter II-8

Table 1: Revenues of Allergan, Inc (2006 & 2007): Breakdown

of Net Sales of Botox/Neuromodulator and Total Revenues (In

US$ Million) II-9

Table 2: European Market for Non-Surgical Cosmetic

Procedures (2006): Percentage Share Breakdown of Revenues by

Leading Players - Allergan, Q-Med, Mentor Corporation,

Mattioli Engineering, Candela, and Others (includes

corresponding Graph/Chart) II-9

Table 3: European Market for Non-Surgical Cosmetic

Procedures (2009): Percentage Breakdown of Revenues by Type

of Procedure -Cosmetic Botulinum Toxin Injections, Facial

Fillers, Microdermabrasion, Chemical Peeling, and Aesthetic

Lasers (includes corresponding Graph/Chart) II-10

Reloxin Emerges to Threaten Allergan's Dominance II-10

Reloxin Vs Botox: A Comparison II-10

Outlook for Allergan's Botox II-11

Market Share Statistics: The New Batting Order II-12

Global II-12

Table 4: World Market for Therapeutic Neurotoxins (2008):

Percentage Breakdown of Revenues by Company/Brand -Botox

(Allergan), Dysport (Ispen), Myobloc (Solstice), and Others

(includes corresponding Graph/Chart) II-12

Table 5: World Market for Cosmetic Neurotoxins (2008):

Percentage Breakdown of Revenues by Company/Brand -

Botox/Vistabel (Allergan) and Dysport/Reloxin

(Ipsen/Medicis) II-12

Europe II-13

Table 6: European Market for Cosmetic Neurotoxins (2008):

Percentage Breakdown of Revenues by Company/Brand -

Botox/Vistabel (Allergan) and Dysport (Ipsen) II-13

Table 7: European Market for Therapeutic Neurotoxins

(2008): Percentage Breakdown of Revenues by Company/Brand -

Botox (Allergan), Dysport (Ispen), and Others (includes

corresponding Graph/Chart) II-13

United States II-13

Table 8: US Market for Therapeutic Neurotoxins (2008):

Percentage Breakdown of Revenues by Company/ Brand -Botox

(Allergan) and Myobloc (Solstice) II-13

Market Share Statistics: Through the Looking Glass: Year 2012 II-14

Global II-14

Table 9: World Market for Therapeutic Neurotoxins (2012P):

Percentage Breakdown of Revenues by Company/ Brand -Botox

(Allergan), Dysport (Ispen), Myobloc (Solstice), Puretox

(Mentor), Xeomin (Merz), and Others (includes

corresponding Graph/Chart) II-14

Table 10: World Market for Cosmetic Neurotoxins (2012P):

Percentage Breakdown of Revenues by Company/Brand -Botox

(Allergan), Dysport/Reloxin (Ipsen/Medicis), Xeomin (Merz),

and Puretox (Mentor) (includes corresponding Graph/Chart) II-14

United States II-14

Table 11: US Market for Therapeutic Neurotoxins (2012P):

Percentage Breakdown of Revenues by Company/Brand -Botox

(Allergan), Myobloc (Solstice), Dysport (Ispen), Puretox

(Mentor) and Xeomin (Merz) (includes corresponding

Graph/Chart) II-14

Table 12: US Market for Cosmetic Neurotoxins (2008 &

2012P): Percentage Breakdown of Revenues by Company/ Brand -

Botox (Allergan), Reloxin (Medicis), and Puretox (Mentor)

(includes corresponding Graph/Chart) II-15

Europe II-15

Table 13: European Market for Therapeutic Neurotoxins

(2012P): Percentage Breakdown of Revenues by Company/Brand -

Botox (Allergan), Dysport (Ispen), Xeomin (Merz) and

Neurobloc (Solstice) (includes corresponding Graph/Chart) II-15

A Peek Into Products Approved & In Pipeline II-16

New Treatment Indications for Botulinum Toxin Compounds/

Brands in Pipeline As of the Year 2008 II-16

List of Botulinum Toxin Products/Brands that are Approved

for Various Cosmetic Therapeutic Indications As of the

Year 2007 II-17

2. Product Overview II-18

Botulinum Toxin: A Poison That Cures II-18

Structure & Mechanism of Action II-18

Disadvantages II-19

Classification of Botulinum Toxin II-19

Botulinum Toxin Type A II-19

Historical Timeline of Botulinum Toxin: 1885-2002 II-20

Botox(R) II-20

Key Characteristics of Botox(R) and Botox(R) Cosmetic II-21

Approvals and Indications of Botox in Select Regions II-21

Common Adverse Reactions with Botox II-22

Dysport(R)/ Reloxin(R) II-22

Key Characteristics of Dysport(R) II-22

PurTox(R) II-23

Key Characteristics of PurTox(R) II-23

Xeomin(R)/ NT-201 II-23

Key Characteristics of Xeomin(R)/ NT-201 II-23

Botulinum Toxin Type B II-23

Myobloc(R)/NeuroBloc(R) II-24

Key Characteristics of Myobloc(R) II-24

Applications of Botulinum Toxin II-24

Cosmetic Applications II-24

Glabellar Lines II-25

Facial Wrinkles II-25

Key Cosmetic Indications for Botulinum Toxin II-25

Therapeutic Applications II-26

Movement Disorders/Pain II-26

Cervical Dystonia II-26

Hemifacial Spasm II-26

Blepharospasm II-26

Strabismus II-26

Chronic Pain II-27

Botox in Migraine Treatment II-27

Hyperhidrosis II-28

Bladder Dysfunctions II-28

Spasticity II-28

Other Applications II-28

3. Recent Industry Activity II-30

Johnson & Johnson Acquires Mentor Corporation II-30

Azzalure(R) Gains Approval from 15 European Countries II-30

Inclusion of New Side Effect in Botox and Botox Cosmetic Labels II-30

Azzalure(R) Gains Approval for Aesthetic Application in the UK II-31

BioForm Medical Acquires Advanced Cosmetic Intervention II-31

Galderma to Acquire CollaGenex II-31

Allergan and Clinique Form Strategic Collaboration II-32

Ipsen and Medicis File BLA for Reloxin(R) II-32

Allergan and Clinique Launch New Skin Care Products II-32

FDA Accepts Ipsen's Filing for Reloxin II-32

GlaxoSmithKline Gains Approval for BOTOX(R) in Japan II-32

Mentor Completes Phase IIIb Trial for Its Botulinum Toxin

Type A Product II-32

Allergan Commences Botox Study for Urological Cases in India II-33

FDA Accepts BLA Filing for Dysport(R) in Cervical Dystonia Cases II-33

Allergan Successfully Completes Analysis of Two Phase III

Trials for BOTOX(R) II-33

Allergan to Set Up a New Subsidiary in India II-33

Allergan Join Hands with India-Based Kaya II-34

Q-Med and Medy-Tox Cancel the Collaboration Agreement II-34

Galderma to Increase Awareness in Brazil II-34

Allergan to Launch New Products in India II-34

Allergan to Establish a State-of-the-Art Botox Training

Institute II-34

Q-Med Inks a Distribution Agreement with Medy -Tox II-35

Q-Med Collaborates with Medy-Tox for a Range of Joint Activities II-35

Medicis Plans Investment in Revance II-35

Galderma Receives Distribution Rights for Dysport (R) II-35

Allergan to Acquire Espirit Pharma II-36

Allergan Launches "Project: Sweat Free" II-36

Solstice Neurosciences Inks Commercialization Agreement II-36

Ipsen Partners with Galderma II-36

Bio-Med Unveils BOTOGenie II-36

Medicis Launches PERLANE II-36

Studies Underway for Botulinum Toxin Usage for Enlarged Calf

Muscles II-37

FDA to Assess Reloxin for Cosmetic Use II-37

Ipsen Inks Development and Distribution Agreement with Medicis II-37

Allergan Rolls Out New Division with Acquisition of Inamed II-37

FTC Mandates Allergan Divest Rights to Reloxin II-37

Medicis Inks Agreement with Ipsen II-38

Solstice Neurosciences Inks Licensing Agreement with DreamPharma II-38

Botox Enters India Market II-38

Mentor Begins Phase-I Clinical Trial on Botulinum Toxin II-38

Allergan Inks Agreement with GlaxoSmithKline II-39

DOR BioPharma Inks Agreement with Dowpharma II-39

Merz Pharma Receives Approval for Botulinum Toxin Type A II-39

Mentor Initiates Phase-I Clinical Trial II-39

Mentor Establishes New Production Facility II-39

DOR BioPharma and Thomas Jefferson University Teams-Up with

US Army II-40

Mentor Inks Licensing Agreement with WARF II-40

Solstice Acquires World Rights for Myobloc II-40

Inamed Rolls Out Reloxin Brand II-40

4. Focus on Select Key Players II-41

Allergan, Inc (USA) II-41

Ipsen Group (France) II-42

Lanzhou Institute of Biological Products (China) II-42

Metabiologics Inc, (USA) II-43

Merz Pharmaceuticals GmbH (Germany) II-43

Mentor Corporation (USA) II-43

Medy-Tox Incorporated (South Korea) II-43

Medicis Pharmaceutical Corporation (USA) II-44

Solstice Neurosciences, Inc. (USA) II-44

5. Global Market Perspective II-45

Table 14: World Recent Past, Current & Future Analysis for

Botulinum Toxin by Geographic Region/Country - US, Europe and

Rest of World Independently Analyzed by Annual Sales in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) II-45

Table 15: World 10-Year Perspective for Botulinum Toxin by

Geographic Region - Percentage Breakdown of Dollar Sales for

US, Europe and Rest of World for the Years 2006, 2009 & 2015

(includes corresponding Graph/Chart) II-45

Table 16: World Recent Past, Current & Future Analysis for

Botulinum Toxin in Cosmetic Applications by Geographic Region -

US, Europe and Rest of World Independently Analyzed by

Annual Sales in US$ Million for the Years 2006 through 2015

(includes corresponding Graph/Chart) II-46

Table 17: World 10-Year Perspective for Botulinum Toxin in

Cosmetic Applications by Geographic Region - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

for the Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-46

Table 18: World Recent Past, Current & Future Analysis for

Botulinum Toxin in Therapeutic Applications by Geographic

Region - US, Europe and Rest of World Independently Analyzed

by Annual Sales in US$ Million for the Years 2006 through 2015

(includes corresponding Graph/Chart) II-47

Table 19: World 10-Year Perspective for Botulinum Toxin in

Therapeutic Applications by Geographic Region - Percentage

Breakdown of Dollar Sales for US, Europe and Rest of World

for the Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-47

Table 20: Global Recent Past, Current & Future Analysis for

Botulinum Toxin in Therapeutic Application by Disease

Indication - Movement Disorders/Pain, Headache, Hyperhidrosis,

Overactive Bladder and Spasticity Analyzed with Annual Sales

Figures in US$ Million for Years 2006 through 2015 (includes

corresponding Graph/Chart) II-48

Table 21: World 10-Year Perspective for Botulinum Toxin in

Therapeutic Application by Disease Indication - Percentage

Breakdown of Dollar Sales for Movement Disorders/Pain,

Headache, Hyperhidrosis, Overactive Bladder and Spasticity

for the Years 2006, 2009 & 2015 (includes corresponding

Graph/Chart) II-48

III. MARKET

1. The United States III-1

A.Market Analysis III-1

Outlook III-1

Cosmetic Procedures: An Overview III-1

Botox Leads the US Botulinum Toxin Market III-2

Botox Approvals and Indications in the US III-2

Market Dynamics III-2

Booming Non-Surgical Treatments III-2

Aging Baby Boomers Drive Aesthetic Business III-2

Expanding Physician Base Extends Impetus to Growth III-3

Demand for Professional Help On the Rise III-3

Direct-to-Consumer Advertising Drive Cosmetic Botulinum Toxin III-3

Medical Spas - Growing in Number III-3

Botulism Poisoning: A Major Concern III-4

Botox Injection - Popular Non-Invasive Cosmetic Procedure III-4

Table 22: Number of Botox Injections (2000-2005) (includes

corresponding Graph/Chart) III-4

Table 23: Botox Injections by Gender (2004) III-4

Table 24: Botox Injections by Age Group (2004) (includes

corresponding Graph/Chart) III-5

Botox Attracts American Men III-5

Table 25: Non-Invasive Cosmetic Procedures in the US

(2005): Percentage of Patients Treated by All US-Based

AACS Members Practices (includes corresponding

Graph/Chart) III-5

Table 26: Cosmetic Procedures (Surgical/ Non-Surgical) in

the US (2005): Percentage of Patients Treated by All

US-Based AACS Members Practices III-6

US Cosmetic Market - Statistical Data III-6

Table 27: Cosmetic Market in the US (2004 & 2005): Leading

Surgical Procedures (includes corresponding Graph/Chart) III-6

Table 28: Cosmetic Market in the US (2004 & 2005): Leading

Non-Surgical Procedures (includes corresponding Graph/

Chart) III-7

Table 29: Number of Cosmetic Procedures in the US (2005):

Percentage Breakdown by Gender III-7

Table 30: Number of Cosmetic Procedures in the US (2005):

Percentage Breakdown by Age Group (includes corresponding

Graph/Chart) III-7

Table 31: Number of Cosmetic Procedures in the US (2005):

Percentage Breakdown by Facility (includes corresponding

Graph/Chart) III-8

Table 32: Cosmetic Market in the US (2004): Percentage

Breakdown by Procedure Type III-8

Strategic Corporate Developments III-8

Key Players III-14

B.Market Analytics III-17

Table 33: US Recent Past, Current & Future Analysis for

Botulinum Toxin by Application - Cosmetic Applications and

Therapeutic Applications (Movement Disorders/Pain, Headache,

Hyperhidrosis, Overactive Bladder, and Spasticity)

Independently Analyzed by Annual Sales Figures in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) III-17

Table 34: US 10-Year Perspective for Botulinum Toxin by

Application - Percentage Breakdown of Dollar Sales for

Cosmetic Applications and Therapeutic Applications (Movement

Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder,

and Spasticity) for the Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) III-18

2. Europe III-19

A.Market Analysis III-19

Outlook III-19

European Market - A Primer III-19

Botox Approvals and Indications in Select European Countries III-19

Botox to Support Radiation Treatments III-19

Strategic Corporate Developments III-20

Key Players III-20

B.Market Analytics III-21

Table 35: European Recent Past, Current & Future Analysis

for Botulinum Toxin by Application - Cosmetic Applications

and Therapeutic Applications (Movement Disorders/Pain,

Headache, Hyperhidrosis, Overactive Bladder, and Spasticity)

Independently Analyzed by Annual Sales Figures in US$

Million for the Years 2006 through 2015 (includes

corresponding Graph/Chart) III-21

Table 36: European 10-Year Perspective for Botulinum Toxin

by Application - Percentage Breakdown of Dollar Sales for

Cosmetic Applications and Therapeutic Applications (Movement

Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder,

and Spasticity) for the Years 2006, 2009 & 2015 (includes

corresponding Graph/Chart) III-22

3. Rest of World III-23

A.Market Analysis III-23

Outlook III-23

Asia III-23

India - An Emerging Market for Botox III-23

South Korea III-23

Table 37: Leading Players in the Korean Botulinum Toxin

Market (2008): Percentage Breakdown of Sales for

Medy-Tox, Allergan, Ipsen, and Lanzhou Institute

(includes corresponding Graph/Chart) III-23

Australia - A Well Supported Market III-24

Botox Approvals and Indications in Select Asian Countries III-24

Botox Approvals and Indications in Select Latin American

Regions III-24

Botox Approvals and Indications in Other Select Global

Regions III-25

Strategic Corporate Developments III-25

Key Players III-28

B.Market Analytics III-29

Table 38: Rest of World Recent Past, Current & Future

Analysis for Botulinum Toxin by Application - Cosmetic

Applications and Therapeutic Applications (Movement

Disorders/Pain, Headache, Hyperhidrosis, Overactive Bladder,

and Spasticity) Independently Analyzed by Annual Sales

Figures in US$ Million for the Years 2006 through 2015

(includes corresponding Graph/Chart) III-29

Table 39: Rest of World 10-Year Perspective for Botulinum

Toxin by Application - Percentage Breakdown of Dollar Sales

for Cosmetic Applications and Therapeutic Applications

(Movement Disorders/Pain, Headache, Hyperhidrosis,

Overactive Bladder, and Spasticity) for the Years 2006,

2009 & 2015 (includes corresponding Graph/Chart) III-30

IV. COMPETITIVE LANDSCAPE

To order this report:

World Botulinum Toxin Market

http://www.reportlinker.com/p0119494/World-Botulinum-Toxin-Market.html

More market research reports here!

    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Reportlinker Adds Biologic Imaging Reagents: Technologies and Global Markets Report
2. Reportlinker Adds Dermatological Therapeutics: Global Markets Report
3. Reportlinker Adds Markets for Advanced Wound Care Technologies Report
4. Reportlinker Adds Antiseptics and Disinfectants Report
5. Reportlinker Adds Commercial Amino Acids Report
6. Reportlinker Adds Membrane & Separation Technology News Review, 2008 Report
7. Reportlinker Adds the Dental Market: Techniques, Equipment and Materials Report
8. Reportlinker Adds Pediatric Health Care Products and Services Report
9. Reportlinker Adds Botanical and Plant-Derived Drugs: Global Markets Report
10. Reportlinker Adds 2008/2009 Healthcare Research Review Report
11. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Omaha, NE (PRWEB) , ... February 12, 2016 , ... ... list of the five most searched jobs via the website of healthcare staffing leader ... professionals in travel nurse jobs , travel therapy positions and in ...
(Date:2/12/2016)... Texas (PRWEB) , ... February 12, 2016 , ... Yisrayl ... a revealing article this week that uncovers what he says are the real facts ... stories of the Bible from parents and Sunday school teachers, and Yisrayl says there ...
(Date:2/12/2016)... ... , ... With the exception of restorative dentistry, to date there has been no other option ... by the FDA, there is a now a new protocol in stopping cavity progression; Silver ... and quick to apply. The application is as simple as drying the tooth and ...
(Date:2/11/2016)... ORLEANS (PRWEB) , ... February 11, 2016 , ... “ ... Achieving Satisfaction through a Well Managed Mind” (published by Balboa Press) teaches readers how ... way of being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding ...
(Date:2/11/2016)... ... February 11, 2016 , ... Student-doctors from Western ... (AOA) Match Program Tuesday, February 9, taking one of the final steps in ... medical education positions across the country. Of the 103 student-doctors who comprise the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 Wearable posture tracker, ALEX , has taken Kickstarter by ... and just seven days left to go, ALEX is said to be delivered to backers starting May ... ... ... Created by ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. (OTC ... 2016 with sales exceeding company targets, are adding key ... their trademark from the United States Patent and Trademark ... , Chief Executive Officer of PLAD, Inc.  In January, ... Pennsylvania with two new customers, Cumberland ...
Breaking Medicine Technology: